Caption Management’s Ocular Therapeutix OCUL Stock Holding History

Caption Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66,800	Closed	-$566K	–	1936
2026 Q1	$566K	Sell	66,800 -548,300	-89%	-$5.23M	﹤0.01%	1180
2025 Q4	$7.47M	Buy	615,100 +565,100	+1,130%	+$6.86M	0.05%	407
2025 Q3	$585K	Hold	50,000	–	–	﹤0.01%	1264
2025 Q2	$464K	Buy	+50,000	New	+$391K	0.01%	1128
2021 Q1	–	Sell	-45,000	Closed	-$933K	–	1288
2020 Q4	$933K	Buy	+45,000	New	+$668K	0.02%	624
2020 Q2	–	Sell	-50,000	Closed	-$248K	–	1129
2020 Q1	$248K	Buy	+50,000	New	+$247K	0.01%	668
2019 Q4	–	Sell	-8,400	Closed	-$26K	–	952
2019 Q3	$26K	Buy	+8,400	New	+$37.5K	﹤0.01%	665

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caption Management's OCUL Position: Q2 2026 in Review

Caption Management reduced its Ocular Therapeutix (OCUL) stake by 90% in Q2 2026, selling an estimated $3.11M and leaving 39,800 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Caption Management first reported a position in OCUL in Q3 2019 and has held it in 7 quarters since. The position peaked at $3.24M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Caption Management held 39,800 shares of Ocular Therapeutix worth $391K as of Q2 2026.
Caption Management sold 342,959 Ocular Therapeutix shares in Q2 2026, an estimated $3.11M.
Ocular Therapeutix made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1375 holding.
Caption Management first reported a position in Ocular Therapeutix in Q3 2019 and has held it in 7 quarters since.
Caption Management's Ocular Therapeutix position peaked at $3.24M in Q1 2026.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.